Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The USFDA has cleared American CryoStem's Investigational New Drug (IND) application for Phase I, to develop ATCell™, a proprietary expanded autologous adipose-derived mesenchymal stem cell therapy for the treatment of Post-Concussion Syndrome (PCS).
Product Name : ATCell
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable